Contagion Editorial Team

Emblaveo for multidrug-resistant infections, advancing RNA therapies and new vaccine options, Vaxart's oral norovirus vaccine, and synthetic gel for ABSSSI, and more.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

This week, five all-oral TB regimens showed efficacy, fungal biofilm diseases remain challenging, over 2 million pastries were recalled due to contamination, and more.

The approval is based on positive phase 3 clinical trial results, offering an effective option for travelers and others at risk of chikungunya, the mosquito-borne illness.

The new version of its molecular test targets the causes of gastroenteritis.

This week, a study on children with invasive candidiasis showed that switching treatment was just as effective, AI is being explored as a tool to combat AMR, and more.

This combination antibiotic is indicated for adults with limited or no treatment options, including gram-negative infections. It will be available in the third quarter of this year.

Cabotegravir (Vocabria) + rilpivirine (Rekambys) is the first and only complete long-acting injectable regimen for the treatment of HIV.

The company said its oral therapy, S-337395, achieved a 88.94% reduction in viral load.

The fully cooked frozen product was not recalled because the product can no longer be purchased. This does apply to consumers who have the product at home.

Nature Medicine published additional data on Vedanta Biosciences’ Clostridioides difficile investigational therapy, VE303, from its phase 2 trial.

The federal agency approved safety labeling changes to the prescribing information for Abrysvo (Pfizer) and Arexvy (GSK) RSV vaccines for seniors after data from clinical trials, reports to the Vaccine Adverse Event Reporting System (VAERS), and a postmarketing study.

From foodborne illness outbreaks to waterborne diseases and beyond, this year saw developments in the gastrointestinal infection space.

This week, concerns over mutated avian flu in a Louisiana patient, the potential of ibuzatrelvir for COVID-19 treatment, a comparison of ceftolozane-tazobactam and ceftazidime-avibactam for pneumonia treatment, and more.

Here are some of the bigger stories on this topic from this year.

A lot of Systane Lubricant Eye Drops Ultra PF has been voluntarily recalled by the manufacturer.

As the year is ending, here are some of the bigger stories Contagion covered on this topic.

As 2024 winds to a close, take a look back on some of the biggest stories Contagion was following around respiratory infections.

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

The ongoing outbreak in the Democratic Republic of Congo is affecting mostly very young children, and has investigators searching for answers.

Here is a recap of the latest happenings during C diff awareness month.

Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.

The clinical stage company, Recursion, dosed its first participant using a novel therapy that is not an antimicrobial.

Experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline, the FDA approved Pfizer's RSV vaccine for adults aged 18 to 59, E coli outbreak linked to McDonald's Quarter Pounders, and more.

This new indication for the bivalent respiratory syncytial virus prefusion F vaccine (Abrysvo) makes it the broadest currently available.

The late-breaking ID Week session reported on the once-weekly oral regimen being studied for use in people with HIV who are virologically suppressed.

At ID Week 2024, ViiV Healthcare reports its long-acting PrEP, cabotegravir (Apretude), is more than 99% effective.

This week, recent investigations link contaminated ice machines to Burkholderia multivorans infections, the hepatitis treatment market is projected to grow to USD 30.2 billion by 2032, 2020 guidelines recommend targeting specific AUC levels for optimizing vancomycin therapy, and more

People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.